(Q28485384)
Statements
miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression (English)
0 references
2012
0 references
7
0 references
11
0 references
e50469
0 references
29 November 2012
1 reference
2 references